Max Planck Institute Study Uncovers Why BET Inhibitors Fail In Clinical Cancer Treatments

New research explains that cancer drugs fail by targeting all BET proteins at once, ignoring the distinct roles of BRD2 and BRD4 in gene activation.

By: AXL Media

Published: Apr 9, 2026, 9:15 AM EDT

Source: Information for this report was sourced from the Max Planck Institute of Immunobiology and Epigenetics via EurekAlert!

The Biological Miscalculation Behind Failed Clinical Trials

For over a decade, a class of pharmaceuticals known as BET inhibitors has entered clinical trials with high expectations, only to deliver largely disappointing results for patients. These drugs were designed to slow tumor growth by blocking "Bromo- and Extra-Terminal domain" proteins, which many cancers rely on to activate oncogenes. However, according to a new study from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, the medical community’s assumption that all BET proteins perform identical functions was a critical oversight. The research, published in Nature Genetics, explains that because current inhibitors block the entire protein family at once, they produce unpredictable effects and significant side cases that limit their effectiveness.

Distinct Roles In The Gene Activation Sequence

The laboratory of Asifa Akhtar has provided a more nuanced understanding of genomic regulation by distinguishing the specific duties of two key proteins, BRD2 and BRD4. While BRD4 is responsible for driving the actual transcription of genes by releasing the enzyme RNA Polymerase II, BRD2 acts much earlier in the process. Researchers compared the activation of a gene to a stage production, where BRD2 serves as the stage manager that organizes props, actors, and machinery before the performance begins. By blocking both proteins simultaneously, current therapies disrupt the preparation and the performance at the same time, leading to context-dependent failures that are difficult for clinicians to predict.

The Discovery Of A Molecular Labeling System

A vital component of this discovery involves how BRD2 identifies where to begin its work on the chromatin. The study found that an enzyme called MOF places specific chemical tags, or histone acetylations, on the DNA complex to act as bookmarks. BRD2 is uniquely sensitive to these specific labels, whereas other BET proteins remain largely unaffected by their removal. According to first author Umut Erdogdu, these acetylated chromatin platforms allow regulatory proteins like BRD2 to concentrate precisely where they are needed. This specificity suggests that BRD2 is a far more critical player in the initiation of gene activity than was previously believed by the scientific community.